MAAS Membership Meeting
May 14 @ 5:30 pm - 8:30 pm
Save the Date!
Michigan Allergy & Asthma Society Membership Meeting
May 14, 2025
Novi Sheraton Hotel
5:30 pm – 6:00 pm “Interconnectivity of Type 2 Inflammation Across Select Diseases“ Todd Mahr, MD, Medical Director of ACAAI, sponsored by Regeneron Mackinaw Room
6:00 pm – 7:00 pm Exhibitor Reception Ballroom A
7:00 pm – 9:00 pm MAAS Business Meeting, Dinner and Presentations Ballroom B
“Allergy Immunology Fellow Presentations”
- Kelsey Finkel, MD – Henry Ford Health System
“Associations between genetic ancestry and serum Immunoglobulin E trajectory, allergen-specific IgE sensitization, and asthma at 10 years among Black children in the WHEALS birth co-hort.”
- Melanie Donahue, MD – University of Michigan
“Investigating mast cell biology with small molecule mediators: taking pharmacologic from bedside to bench (and hopefully back again)”
- Ruizhi Dong, MD – University of Michigan
“Evaluation of Baseline Apolipoprotein A1 Anaphylaxis and Mastocytosis”
- Saad Anjum, MD – Detroit’s Children’s Hospital of Michigan
“Implementing an Inpatient Community Healthcare Worker for Children with Asthma”
- Devika Pillay, DO – Detroit’s Children’s Hospital of Michigan
“The Use of Electronic Monitoring Device for Wheezing and Remote Monitoring Program (RMP) to Improve Asthma Outcomes.”
- Aayushi Mehta, MD – University of Michigan
“Baseline Tryptase Correlation with Reactions to Allergen and Venom Immunotherapy”
Objectives:
– Discuss the Relationship Between Genetic Ancestry and Allergic Disease Risk
– Evaluate the Implications of Ancestry-Related Findings on Clinical Practice
– Identify Gaps in Current Asthma and Allergy Guidelines Related to Genetic Ancestry
– Discuss the effect of FAK modulation on mast cell degranulation as well as mouse models of anaphylaxis.
– Discuss the current data regarding using Apolipoprotein A1 as a biomarker to risk stratify patients on their anaphylaxis risk.
– Identify impact of RMP and wheeze detector device on asthma patients in Detroit.
– Recognize whether a screening tryptase is clinically valuable.